Zomedica Pharmaceuticals Corp Stock Price To Earning

ZOM Stock  USD 0.12  0  2.50%   
Zomedica Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Zomedica Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zomedica Stock. The fundamental analysis module provides a way to measure Zomedica Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zomedica Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Zomedica Pharmaceuticals Corp Company Price To Earning Analysis

Zomedica Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Zomedica Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Zomedica Pharmaceuticals is extremely important. It helps to project a fair market value of Zomedica Stock properly, considering its historical fundamentals such as Price To Earning. Since Zomedica Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zomedica Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zomedica Pharmaceuticals' interrelated accounts and indicators.
1.0-0.55-0.950.840.940.91-0.130.990.890.820.910.950.880.910.660.880.960.910.960.99
1.0-0.55-0.940.830.940.91-0.130.990.890.810.910.950.880.90.660.870.960.910.970.99
-0.55-0.550.41-0.45-0.79-0.160.08-0.55-0.17-0.45-0.28-0.31-0.12-0.47-0.98-0.19-0.61-0.84-0.54-0.47
-0.95-0.940.41-0.91-0.85-0.930.12-0.95-0.96-0.91-0.96-0.94-0.94-0.94-0.54-0.94-0.88-0.8-0.92-0.94
0.840.83-0.45-0.910.80.79-0.150.850.810.890.910.780.780.980.550.920.770.760.80.78
0.940.94-0.79-0.850.80.72-0.130.940.710.780.780.810.690.860.860.720.940.990.910.9
0.910.91-0.16-0.930.790.72-0.120.910.980.760.960.980.990.860.310.960.820.650.870.93
-0.13-0.130.080.12-0.15-0.13-0.12-0.13-0.11-0.19-0.14-0.13-0.12-0.16-0.1-0.14-0.13-0.13-0.14-0.13
0.990.99-0.55-0.950.850.940.91-0.130.880.80.930.960.880.920.670.880.940.90.950.98
0.890.89-0.17-0.960.810.710.98-0.110.880.80.940.950.990.850.310.940.790.640.850.91
0.820.81-0.45-0.910.890.780.76-0.190.80.80.840.770.790.880.550.840.740.740.790.77
0.910.91-0.28-0.960.910.780.96-0.140.930.940.840.950.940.960.440.990.820.710.870.91
0.950.95-0.31-0.940.780.810.98-0.130.960.950.770.950.970.870.460.920.870.740.910.98
0.880.88-0.12-0.940.780.690.99-0.120.880.990.790.940.970.840.270.950.790.610.850.91
0.910.9-0.47-0.940.980.860.86-0.160.920.850.880.960.870.840.590.940.840.820.870.86
0.660.66-0.98-0.540.550.860.31-0.10.670.310.550.440.460.270.590.330.690.890.630.59
0.880.87-0.19-0.940.920.720.96-0.140.880.940.840.990.920.950.940.330.780.650.840.87
0.960.96-0.61-0.880.770.940.82-0.130.940.790.740.820.870.790.840.690.780.940.990.94
0.910.91-0.84-0.80.760.990.65-0.130.90.640.740.710.740.610.820.890.650.940.90.86
0.960.97-0.54-0.920.80.910.87-0.140.950.850.790.870.910.850.870.630.840.990.90.96
0.990.99-0.47-0.940.780.90.93-0.130.980.910.770.910.980.910.860.590.870.940.860.96
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Zomedica Retained Earnings

Retained Earnings

(162.39 Million)

Zomedica Pharmaceuticals reported last year Retained Earnings of (170.93 Million)
Based on the latest financial disclosure, Zomedica Pharmaceuticals Corp has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Zomedica Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zomedica Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zomedica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics of similar companies.
Zomedica Pharmaceuticals is currently under evaluation in price to earning category among its peers.

Zomedica Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Zomedica Pharmaceuticals from analyzing Zomedica Pharmaceuticals' financial statements. These drivers represent accounts that assess Zomedica Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zomedica Pharmaceuticals' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap35.2M84.0M293.2M159.7M196.2M206.0M
Enterprise Value34.7M23.9M99.6M134.1M186.0M195.3M

Zomedica Fundamentals

About Zomedica Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Zomedica Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zomedica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zomedica Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:
Check out Zomedica Pharmaceuticals Piotroski F Score and Zomedica Pharmaceuticals Altman Z Score analysis.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.06)
Revenue Per Share
0.027
Quarterly Revenue Growth
0.018
Return On Assets
(0.09)
Return On Equity
(0.24)
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.